Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced they have signed an exclusive license with the Massachusetts Institute of Technology (MIT) for a family of Lipid Nanoparticle (LNP) technologies developed in the lab of Dr. Daniel G. Anderson, a scientific founder and advisory board member of CRISPR Therapeutics. Under the terms of the license, CRISPR Therapeutics obtains the exclusive rights to use the LNP technologies in their therapeutic development programs focused on in vivo gene editing applications. MIT receives an upfront technology access fee, milestones, and royalties on licensed products that reach the market.   “We have been working to evaluate a panel of different LNP technologies for in vivo editing applications based on their potency and tolerability. These specific compounds from Dr. Anderson’s lab continue to perform well relative to others we have tested, and we are excited to sign this license with MIT. The primary focus here is liver indications, where we are continuing to optimize our platform for both gene disruption and correction, and have demonstrated very potent gene disruption in murine liver,” said Dr. Chad Cowan, Head of Research at CRISPR Therapeutics. Dr. Anderson is an Associate Professor of Chemical Engineering and the Institute for Medical Engineering and Science, and member of the Koch Institute for Integrative Cancer Research at MIT.  He is a world-leader in the development of advanced drug delivery systems for non-viral gene delivery.  He was also one of the first to demonstrate the potential for in vivo gene editing using CRISPR/Cas9. “Our laboratory has worked to develop non-viral delivery vectors for nucleic acids, and we are finding that LNP technologies work very well for delivering the CRISPR/Cas9 system. In fact, gene editing applications may be particularly well-suited to LNP delivery given the potential for single dose efficacy. I am excited to see CRISPR-based in vivo therapies moving rapidly toward the clinic,” said Dr. Daniel Anderson. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com. CRISPR Forward-Looking Statement Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical and clinical studies for the Company’s product candidates; uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; availability and timing of results from preclinical and clinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made.


BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced they have signed an exclusive license with the Massachusetts Institute of Technology (MIT) for a family of Lipid Nanoparticle (LNP) technologies developed in the lab of Dr. Daniel G. Anderson, a scientific founder and advisory board member of CRISPR Therapeutics. Under the terms of the license, CRISPR Therapeutics obtains the exclusive rights to use the LNP technologies in their therapeutic development programs focused on in vivo gene editing applications. MIT receives an upfront technology access fee, milestones, and royalties on licensed products that reach the market.   “We have been working to evaluate a panel of different LNP technologies for in vivo editing applications based on their potency and tolerability. These specific compounds from Dr. Anderson’s lab continue to perform well relative to others we have tested, and we are excited to sign this license with MIT. The primary focus here is liver indications, where we are continuing to optimize our platform for both gene disruption and correction, and have demonstrated very potent gene disruption in murine liver,” said Dr. Chad Cowan, Head of Research at CRISPR Therapeutics. Dr. Anderson is an Associate Professor of Chemical Engineering and the Institute for Medical Engineering and Science, and member of the Koch Institute for Integrative Cancer Research at MIT.  He is a world-leader in the development of advanced drug delivery systems for non-viral gene delivery.  He was also one of the first to demonstrate the potential for in vivo gene editing using CRISPR/Cas9. “Our laboratory has worked to develop non-viral delivery vectors for nucleic acids, and we are finding that LNP technologies work very well for delivering the CRISPR/Cas9 system. In fact, gene editing applications may be particularly well-suited to LNP delivery given the potential for single dose efficacy. I am excited to see CRISPR-based in vivo therapies moving rapidly toward the clinic,” said Dr. Daniel Anderson. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com. CRISPR Forward-Looking Statement Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical and clinical studies for the Company’s product candidates; uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; availability and timing of results from preclinical and clinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made.


BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced they have signed an exclusive license with the Massachusetts Institute of Technology (MIT) for a family of Lipid Nanoparticle (LNP) technologies developed in the lab of Dr. Daniel G. Anderson, a scientific founder and advisory board member of CRISPR Therapeutics. Under the terms of the license, CRISPR Therapeutics obtains the exclusive rights to use the LNP technologies in their therapeutic development programs focused on in vivo gene editing applications. MIT receives an upfront technology access fee, milestones, and royalties on licensed products that reach the market.   “We have been working to evaluate a panel of different LNP technologies for in vivo editing applications based on their potency and tolerability. These specific compounds from Dr. Anderson’s lab continue to perform well relative to others we have tested, and we are excited to sign this license with MIT. The primary focus here is liver indications, where we are continuing to optimize our platform for both gene disruption and correction, and have demonstrated very potent gene disruption in murine liver,” said Dr. Chad Cowan, Head of Research at CRISPR Therapeutics. Dr. Anderson is an Associate Professor of Chemical Engineering and the Institute for Medical Engineering and Science, and member of the Koch Institute for Integrative Cancer Research at MIT.  He is a world-leader in the development of advanced drug delivery systems for non-viral gene delivery.  He was also one of the first to demonstrate the potential for in vivo gene editing using CRISPR/Cas9. “Our laboratory has worked to develop non-viral delivery vectors for nucleic acids, and we are finding that LNP technologies work very well for delivering the CRISPR/Cas9 system. In fact, gene editing applications may be particularly well-suited to LNP delivery given the potential for single dose efficacy. I am excited to see CRISPR-based in vivo therapies moving rapidly toward the clinic,” said Dr. Daniel Anderson. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com. CRISPR Forward-Looking Statement Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical and clinical studies for the Company’s product candidates; uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; availability and timing of results from preclinical and clinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made.


News Article | May 2, 2017
Site: www.eurekalert.org

The National Academy of Sciences announced today the election of 84 new members and 21 foreign associates in recognition of their distinguished and continuing achievements in original research. The National Academy of Sciences announced today the election of 84 new members and 21 foreign associates in recognition of their distinguished and continuing achievements in original research. Those elected today bring the total number of active members to 2,290 and the total number of foreign associates to 475. Foreign associates are nonvoting members of the Academy, with citizenship outside the United States. Newly elected members and their affiliations at the time of election are: Bates, Frank S.; Regents Professor, department of chemical engineering and materials science, University of Minnesota, Minneapolis Beilinson, Alexander; David and Mary Winton Green University Professor, department of mathematics, The University of Chicago, Chicago Bell, Stephen P.; investigator, Howard Hughes Medical Institute; and professor of biology, department of biology, Massachusetts Institute of Technology, Cambridge Bhatia, Sangeeta N.; John J. (1929) and Dorothy Wilson Professor, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge Buzsáki, György; professor, Neuroscience Institute, departments of physiology and neuroscience, New York University Langone Medical Center, New York City Carroll, Dana; distinguished professor, department of biochemistry, University of Utah School of Medicine, Salt Lake City Cohen, Judith G.; Kate Van Nuys Page Professor of Astronomy, department of astronomy, California Institute of Technology, Pasadena Crabtree, Robert H.; Conkey P. Whitehead Professor of Chemistry, department of chemistry, Yale University, New Haven, Conn. Cronan, John E.; professor and head of microbiology, professor of biochemistry, and Microbiology Alumni Professor, department of microbiology, University of Illinois, Urbana-Champaign Cummins, Christopher C.; Henry Dreyfus Professor of Chemistry, Massachusetts Institute of Technology, Cambridge Darensbourg, Marcetta Y.; distinguished professor of chemistry, department of chemistry, Texas A&M University, College Station DeVore, Ronald A.; The Walter E. Koss Professor and distinguished professor, department of mathematics, Texas A&M University, College Station Diamond, Douglas W.; Merton H. Miller Distinguished Service Professor of Finance, The University of Chicago, Chicago Doe, Chris Q.; investigator, Howard Hughes Medical Institute; and professor of biology, Institute of Molecular Biology, University of Oregon, Eugene Duflo, Esther; Co-founder and co-Director of the Abdul Latif Jameel Poverty Action Lab, and Professor of Poverty Alleviation and Development Economics, Massachusetts Institute of Technology, Cambridge Edwards, Robert Haas; professor of neurology and physiology, University of California, San Francisco Firestone, Mary K.; professor and associate dean of instruction and student affairs, department of environmental science policy and management, University of California, Berkeley Fischhoff, Baruch; Howard Heinz University Professor, department of social and decision sciences and department of engineering and public policy, Carnegie Mellon University, Pittsburgh Ginty, David D.; investigator, Howard Hughes Medical Institute; and Edward R. and Anne G. Lefler Professor of Neurobiology, department of neurobiology, Harvard Medical School, Boston Glass, Christopher K.; professor of cellular and molecular medicine and professor of medicine, University of California, San Diego Goldman, Yale E.; professor, department of physiology, Pennsylvania Muscle Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia González, Gabriela; spokesperson, LIGO Scientific Collaboration; and professor, department of physics and astronomy, Louisiana State University, Baton Rouge Hagan, John L.; John D. MacArthur Professor of Sociology and Law, department of sociology, Northwestern University, Evanston, Ill. Hatten, Mary E.; Frederick P. Rose Professor, laboratory of developmental neurobiology, The Rockefeller University, New York City Hebard, Arthur F.; distinguished professor of physics, department of physics, University of Florida, Gainesville Jensen, Klavs F.; Warren K. Lewis Professor of Chemical Engineering and professor of materials science and engineering, Massachusetts Institute of Technology, Cambridge Kahn, Barbara B.; vice chair for research strategy and George R. Minot Professor of Medicine at Harvard Medical School, Beth Israel Deaconess Medical Center, Boston Kinder, Donald R.; Philip E. Converse Collegiate Professor of Political Science and Psychology and research scientist, department of political science, Center for Political Studies, Institute for Social Research, University of Michigan, Ann Arbor Lazar, Mitchell A.; Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, and director, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia Locksley, Richard M.; investigator, Howard Hughes Medical Institute; and professor, department of medicine (infectious diseases), and Marion and Herbert Sandler Distinguished Professorship in Asthma Research, University of California, San Francisco Lozano, Guillermina; professor and chair, department of genetics, The University of Texas M.D. Anderson Cancer Center, Houston Mavalvala, Nergis; Curtis and Kathleen Marble Professor of Astrophysics and associate head, department of physics, Massachusetts Institute of Technology, Cambridge Moore, Jeffrey Scott; Murchison-Mallory Professor of Chemistry, department of chemistry, University of Illinois, Urbana-Champaign Moore, Melissa J.; chief scientific officer, mRNA Research Platform, Moderna Therapeutics, Cambridge, Mass.; and Eleanor Eustis Farrington Chair of Cancer Research Professor, RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester Nunnari, Jodi M.; professor, department of molecular and cellular biology, University of California, Davis O'Farrell, Patrick H.; professor of biochemistry and biophysics, department of biochemistry and biophysics, University of California, San Francisco Ort, Donald R.; research leader and Robert Emerson Professor, USDA/ARS Global Change and Photosynthesis Research Unit, departments of plant biology and crop sciences, University of Illinois, Urbana-Champaign Parker, Gary; professor, department of civil and environmental engineering and department of geology, University of Illinois, Urbana-Champaign Patapoutian, Ardem; investigator, Howard Hughes Medical Institute; and professor, department of molecular and cellular neuroscience, The Scripps Research Institute, La Jolla, Calif. Pellegrini, Claudio; distinguished professor emeritus, department of physics and astronomy, University of California, Los Angeles Pikaard, Craig, S.; investigator, Howard Hughes Medical Institute and Gordon and Betty Moore Foundation; and distinguished professor of biology and molecular and cellular biochemistry, department of biology, Indiana University, Bloomington Read, Nicholas; Henry Ford II Professor of Physics and professor of applied physics and mathematics, Yale University, New Haven, Conn. Roediger, Henry L.; James S. McDonnell Distinguished and University Professor of Psychology, department of psychology and brain sciences, Washington University, St. Louis Rosenzweig, Amy C.; Weinberg Family Distinguished Professor of Life Sciences, and professor, departments of molecular biosciences and of chemistry, Northwestern University, Evanston, Ill. Seto, Karen C.; professor, Yale School of Forestry and Environmental Studies, New Haven, Conn. Seyfarth, Robert M.; professor of psychology and member of the graduate groups in anthropology and biology, University of Pennsylvania, Philadelphia Sibley, L. David; Alan A. and Edith L. Wolff Distinguished Professor in Molecular Microbiology, department of molecular microbiology, Washington University School of Medicine, St. Louis Spielman, Daniel A.; Henry Ford II Professor of Computer Science and Mathematics, departments of computer science and mathematics, Yale University, New Haven, Conn. Sudan, Madhu; Gordon McKay Professor of Computer Science, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Mass. Tishkoff, Sarah; David and Lyn Silfen University Professor, departments of genetics and biology, University of Pennsylvania, Philadelphia Van Essen, David C.; Alumni Professor of Neurobiology, department of anatomy and neurobiology, Washington University School of Medicine, St. Louis Vidale, John E.; professor, department of earth and space sciences, University of Washington, Seattle Wennberg, Paul O.; R. Stanton Avery Professor of Atmospheric Chemistry and Environmental Science and Engineering, California Institute of Technology, Pasadena Wilson, Rachel I.; Martin Family Professor of Basic Research in the Field of Neurobiology, department of neurobiology, Harvard Medical School, Boston Zachos, James C.; professor, department of earth and planetary sciences, University of California, Santa Cruz, Santa Cruz Newly elected foreign associates, their affiliations at the time of election, and their country of citizenship are: Addadi, Lia; professor and Dorothy and Patrick E. Gorman Chair of Biological Ultrastructure, department of structural science, Weizmann Institute of Science, Rehovot, Israel (Israel/Italy) Folke, Carl; director and professor, The Beijer Institute of Ecological Economics, Royal Swedish Academy of Sciences, Stockholm, Sweden (Sweden) Freeman, Kenneth C.; Duffield Professor of Astronomy, Mount Stromlo and Siding Spring Observatories, Research School of Astronomy and Astrophysics, Australian National University, Weston Creek (Australia) Lee, Sang Yup; distinguished professor, dean, and director, department of chemical and biomolecular engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea (South Korea) Levitzki, Alexander; professor of biochemistry, unit of cellular signaling, department of biological chemistry, The Hebrew University of Jerusalem, Jerusalem (Israel) Peiris, Joseph Sriyal Malik; Tam Wah-Ching Professorship in Medical Science, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong, People's Republic of China (Sri Lanka) Robinson, Carol Vivien; Dr. Lee's Professor of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, England (United Kingdom) Thesleff, Irma; academician of science, professor, and research director, developmental biology program, Institute of Biotechnology, University of Helsinki, Helsinki (Finland) Underdal, Arild; professor of political science, department of political science, University of Oslo, Oslo, Norway (Norway) The National Academy of Sciences is a private, nonprofit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognizes achievement in science by election to membership, and -- with the National Academy of Engineering and the National Academy of Medicine -- provides science, engineering, and health policy advice to the federal government and other organizations.

Loading Institute for Medical Engineering and Science collaborators
Loading Institute for Medical Engineering and Science collaborators